PSMA-targeted NIR dyes and their uses

Inventors

Kularatne, Sumith A. • Gagare, Pravin • Myers, Carrie

Assignees

On Target Laboratories Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9968691-B2

Patent

Publication Date

2018-05-15

Expiration Date


Abstract

The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Core Innovation

The disclosed subject matter comprises PSMA-targeted near-infrared dye conjugates having the formula B-X-Y-Z for optical imaging of PSMA-expressing tumors. In this structure, B comprises DUPA or a derivative thereof, X is EAOA, Y is selected from specified peptide sequences, and Z comprises S0456. Disclosed embodiments include variations in spacer lengths, peptide compositions, and sulfonated cyanine dye variants such as DUPA-EAOA-Tyr-S0456, alongside stereoisomeric and structural variants with linker and dye substitutions.

Conjugates with at least a seven-atom spacer show substantially stronger PSMA binding than three-atom-spacer analogues in 22Rv1 cells. The compounds exhibit near-infrared fluorescence, concentration-dependent cell binding, optical signal generation, and tumor-to-background fluorescence for cell identification and image construction. Structural embodiments vary in amino-acid composition, linker segments, and dye substituents, with compound 35 identified as preferred. Because the background section is not included in the provided content, the problem being solved is not explicitly described in patent.

Claims Coverage

The provided claims identify independent claims directed to a compound having formula B-X-Y-Z and a compound selected from a group, along with dependent claims covering optical properties, imaging methods, and instrumentation, comprising six inventive features.

DUPA-based compound structure

Claim 1 recites a compound having the formula B-X-Y-Z, wherein B comprises DUPA or a derivative thereof; X is EAOA; Y is selected from phenylalanine-tyrosine, histidine-tyrosine, phenylalanine-arginine-tyrosine, and histidine-tyrosine; and Z comprises S0456.

Compound selected from a group

Claim 2 recites a compound selected from a group, wherein the group members are not specified in the provided claim text.

Optical properties

A dependent claim specifies absorption and emission maxima between about 500 nm and about 900 nm.

Optical imaging and image construction

The claims describe optical imaging using the compound and specify that the optical signal emitted by the compound can be detected and used to construct an image.

Target-cell identification

A claimed method identifies a target cell type in a biological sample by contacting the sample with the compound and optically detecting whether it is present.

Optical signal detection instruments and tissue types

Dependent claims specify detection of the optical signal using an endoscope, catheter, tomographic system, hand-held optical imaging system, surgical goggles, or intra-operative microscope, and identify biological tissue selected from prostate, bladder, pancreatic, liver, lung, kidney, sarcoma, breast, brain, neuroendocrine carcinoma, colon, testicular, and melanoma cells.

The claims cover the specified DUPA-based fluorescent compound structures and define associated optical properties, optical imaging and target-cell identification methods, signal-detection instruments, and target biological tissues.

Stated Advantages

Conjugates with at least a 7-atom spacer show substantially stronger PSMA binding than 3-atom-spacer analogues in 22Rv1 prostate cancer cells.

DUPA-EAOA-Tyr-S0456 has a reported K_D of 15.2 nM and the best tumor-to-background ratio and tumor fluorescence among the initial spacer series.

The conjugates are described as intended to improve PSMA binding, fluorescence, solubility, pharmacokinetics, tumor accumulation, clearance, and tumor-to-background contrast.

The stated imaging properties may enable detection of smaller or deeper lesions.

The description states that the properties may enable lower doses and cleaner surgical margins.

Documented Applications

Optical imaging of PSMA-expressing prostate tumors, including tumor imaging in 22Rv1 xenograft mice and serial or time-course in vivo fluorescence imaging.

Optical detection, diagnosis, and image-guided cancer surgery or resection of PSMA-expressing tumors.

Identifying a target cell type in a biological sample by contacting the sample with the compound and optically detecting whether the compound is present, including prostate, bladder, pancreatic, liver, lung, kidney, sarcoma, breast, brain, neuroendocrine carcinoma, colon, testicular, and melanoma cells.

Optical imaging using the compound to detect emitted optical signals and construct images using an endoscope, catheter, tomographic system, hand-held optical imaging system, surgical goggles, or intra-operative microscope.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.